Oxcarbazepine
Brand names: Oxcarbazepine Er, Trileptal, Oxcarbazepine, Oxtellar Xr
At a glance
- Medicare prescriptions, 2024
- 977,811
- Medicare drug cost
- $71.2M
- Average cost per prescription
- $72.77
- Clinicians who prescribed it
- 29,474
Where it is prescribed
List the prescribers in any state, county, city or ZIP code →
What it is used for
Oxcarbazepine tablets is indicated for use as monotherapy or adjunctive therapy in the treatment of partial-onset seizures in adults and as monotherapy in the treatment of partial-onset seizures in pediatric patients aged 4 years and above, and as adjunctive therapy in pediatric patients aged 2 years and above with partial-onset seizures.
From the FDA-approved prescribing information (label dated October 2026). Full labels on DailyMed (opens in a new tab)
Who prescribes it
- Neurology 21.3%
- Psychiatry 19.8%
- Psychiatric Nurse Practitioners 19.5%
- Nurse Practitioners 11.8%
- Internal Medicine 8.6%
- Family Medicine 8.4%
- Physician Assistants 4.7%
- Geriatric Medicine 1.1%
- Child & Adolescent Psychiatry 0.9%
- General Practice 0.6%
- Pain Medicine 0.5%
- Child Neurology 0.4%
All prescribers, by place, name or specialty →
Share of Medicare prescriptions written by each specialty. Select one to list its prescribers.
Trend, 2019–2024
Medicare prescriptions rose 5% from 2019 to 2024.
Biggest change by state since 2019
- Kansas +25%
- Alabama +20%
- Florida +16%
- Wisconsin +15%
- Arkansas +14%
- Massachusetts (smallest change) −15%
- South Carolina (smallest change) −13%
From CMS’s yearly state and national Part D summaries, which count every prescriber, including those CMS leaves out of its per-clinician data (fewer than 11 prescriptions). That is why these totals are higher than the count at the top of this page. Prescriptions include refills.
What it looks like
Pills from 5 makers on file. The same medicine can look different depending on who made it, so check the imprint (the letters and numbers on the pill) with your pharmacist if a refill looks different.
Ascend Laboratories, LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 60 mg | white suspension | |
Novartis Pharmaceuticals Corporation
| Strength | Looks like | Imprint |
|---|---|---|
| 150 mg | green oval tablet, 11 mm, scored to split in 2 | T D C G |
| 300 mg | yellow oval tablet, 15 mm, scored to split in 2 | TE TE CG CG |
| 600 mg | pink oval tablet, 19 mm, scored to split in 2 | TF TF CG CG |
Supernus Pharmaceuticals, Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 150 mg | yellow oval tablet, 13 mm | 150 |
| 300 mg | brown oval tablet, 16 mm | 300 |
| 600 mg | red oval tablet, 19 mm | 600 |
Umedica Laboratories USA Inc.
| Strength | Looks like | Imprint |
|---|---|---|
| 150 mg | brown oval tablet, 11 mm, scored to split in 2 | OX 150 |
| 300 mg | yellow oval tablet, 15 mm, scored to split in 2 | OX 300 |
| 600 mg | pink oval tablet, 19 mm, scored to split in 2 | OX 600 |
Zameer Pharmaceuticals LLC
| Strength | Looks like | Imprint |
|---|---|---|
| 150 mg | brown oval tablet, 11 mm, scored to split in 2 | OX 150 |
| 300 mg | yellow oval tablet, 15 mm, scored to split in 2 | OX 300 |
| 600 mg | pink oval tablet, 19 mm, scored to split in 2 | OX 600 |
Source: DailyMed (U.S. National Library of Medicine), from each maker’s FDA drug listing. A few makers are shown, not every one. Never take a pill you can’t identify; ask a pharmacist.
Industry payments about this drug
No industry payments to clinicians named this drug in 2025.
Recalls and shortages
Not on the FDA drug shortage list.
1 recall since 2020
- Nov 2022 · Sun Pharmaceutical Industries Inc · Class II
Presence of foreign substance
Recalls usually affect specific lots from one maker, not every version of a drug. Class I is the most serious; most drug recalls are Class II. FDA recalls (opens in a new tab)
Sources: CMS Medicare Part D Prescribers by Provider and Drug (2024; prescriptions include refills, and CMS hides counts under 11 per prescriber); U.S. Food and Drug Administration, openFDA (drug labels, NDC directory, enforcement reports, drug shortages); CMS Open Payments 2025; ClinicalTrials.gov. General information only, not medical advice; not yet reviewed by our medical reviewer.